Open philanthropy (doctrine)

Piezo Therapeutics Launches to Transform Delivery of Nucleic Acid Medicines

Retrieved on: 
Thursday, January 19, 2023
Gene expression, VentureLab, COVID, Global health, Therapy, COVID-19, RNA transfection, Open philanthropy (doctrine), DNA, Safety, Science Publishing Group, Vaccine, Drug development, Partnership, Engineering, Georgia Tech Research Institute, Regent, RNA, National Academy of Inventors, Sundell, National academy, Medical device, Management, Pharmaceutical industry, Piezo, Georgia Tech

ATLANTA, Jan. 19, 2023 /PRNewswire-PRWeb/ -- Piezo Therapeutics launched with $2 million in seed funding from Open Philanthropy to develop its platform: a simple and affordable way of delivering RNA and DNA medicines, including vaccines and therapeutic proteins. Piezo's platform combines electric pulses and microneedles to deliver nucleic acid medicines safely and efficiently while accelerating manufacturing, easing access, and minimizing costs.

Key Points: 
  • Piezo is developing a simple, affordable, and scalable platform designed for rapid, safe, and efficient delivery of nucleic acid medicines, including RNA/DNA vaccines, therapeutic proteins, and dermal gene therapies.
  • Invented by Georgia Tech researchers, Piezo launches with $2 million in seed funding from Open Philanthropy.
  • Piezo's platform combines electric pulses and microneedles to deliver nucleic acid medicines safely and efficiently while accelerating manufacturing, easing access, and minimizing costs.
  • While this platform has high applicability for vaccines (Piezo's immediate focus), it is designed for a broad array of nucleic acid therapeutics.

BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID

Retrieved on: 
Wednesday, October 5, 2022
Time-invariant system, D2, Atherosclerosis, Sepsis, United States Department of Health and Human Services, Breathe Me, Biomedical Advanced Research and Development Authority, Disease, Hospital, Sickle cell disease, Coagulation, Indapamide, Pandemic, Spironolactone, Development, Human services, Pulmonary hypertension, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Education, COVID, Allergic rhinitis, Medicine, Patient, Thrombosis, Open philanthropy (doctrine), Ogletree, Degenerative disease, Immune system, Administration, Company, PGD2, Health, Hypoxemia, Department, Blood, A2, Biolink zones, Eplerenone, Prostaglandin D2, Thromboxane A2, Philanthropy, COVID-19, Mouth, Silicosis, Pharmaceutical industry, Ramatroban

BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.

Key Points: 
  • BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.
  • Ramatroban has been approved and used in Japan for over 20 years for treatment of allergic rhinitis by twice daily oral administration.
  • BioLink Life Sciences is a North Carolina based clinical research company that develops novel, proprietary pharmaceutical products via multiple regulatory pathways.
  • KARE Biosciences is also developing a novel, antihypertensive combination of indapamide, the best-in-class thiazide-like diuretic, in combination with a mineralocorticoid receptor antagonist (spironolactone or eplerenone).

Infectious Disease Expert Pardis Sabeti, M.D., Ph.D. Joins Board of The 221b Foundation

Retrieved on: 
Thursday, September 15, 2022
Institute, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Precision medicine, Engineering, Department, COVID-19, Infection, FDA, Disease, Center, CRISPR, Immunology, Ministry, Severe acute respiratory syndrome coronavirus 2, Health in Nepal, MIT, Intellectual property, IP, Harvard University, Cancer, History, Organism, CEO, Technology, Biology, Pardis, Public health, Board of directors, Foundation, Lassa fever, Diagnosis, Howard Hughes Medical Institute, Open philanthropy (doctrine), Board, PCR, Broad Institute, Pharmaceutical industry, Vaccine, Management

"CRISPR is uniquely suited to meet the global need for accurate, rapid and affordable diagnostic testing," said Bryan DeChairo, board member of The 221b Foundation and president and CEO of Sherlock Biosciences.

Key Points: 
  • "CRISPR is uniquely suited to meet the global need for accurate, rapid and affordable diagnostic testing," said Bryan DeChairo, board member of The 221b Foundation and president and CEO of Sherlock Biosciences.
  • Pardis has been a fierce global health advocate for her entire career, and will provide invaluable counsel as we deliver on our mission."
  • Through donations of equipment and resources, The 221b Foundation provided much needed support to help Nepal stem the spread of COVID-19 and bolster the countries testing strategy.
  • The Foundation provides global health partners with access to Sherlock Biosciences' products and IP through distribution and licensing.

Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial

Retrieved on: 
Tuesday, June 7, 2022
Oncology, Health, Clinical Trials, Pharmaceutical, Biotechnology, Veterinary, ASU, Arizona State University, Research, University of California, Davis, Knowledge, Veterinary medicine, Invention, Open philanthropy (doctrine), DSMB, Ageing, CEO, Veterinarian, RNA, Cancer, COVID-19, Hope, UC, PI, Multimedia, School, University, Vaccine, The Biodesign Institute, Risk, Data monitoring committee, Dog, Colorado State University, Diagnosis, Population, History, Health, Fire, Safety, Pharmaceutical industry, Medical imaging

Phoenix, Arizona, healthcare company Calviri, Inc., has completed full enrollment in the Vaccine Against Canine Cancer Study (VACCS), with 800 dogs, making it the largest interventional canine clinical trial in the history of veterinary medicine.

Key Points: 
  • Phoenix, Arizona, healthcare company Calviri, Inc., has completed full enrollment in the Vaccine Against Canine Cancer Study (VACCS), with 800 dogs, making it the largest interventional canine clinical trial in the history of veterinary medicine.
  • View the full release here: https://www.businesswire.com/news/home/20220607005397/en/
    The double-blinded trial is testing Calviris vaccine aimed at broadly preventing cancers in dogs.
  • This trial has been a great learning experience for developing the improved preventative vaccine that we are currently producing, as well as new therapeutic vaccines we plan.
  • Calviri is focused on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer.

Los Angeles Business Journal Recognizes Kaufman Legal Group's Joseph Guardarrama as a Minority Leader of Influence

Retrieved on: 
Thursday, February 3, 2022
Fairness, Organization, Trade, Government, Daily Journal Corporation, Private law, Election law, Federal Election Campaign Act, PACS, Los Angeles Business Journal, Social justice, Open philanthropy (doctrine), Association, Private practice, Patient, SEIU United Healthcare Workers West, Public relations

LOS ANGELES, Feb. 3, 2022 /PRNewswire/ -- Boutique political and government law firm Kaufman Legal Group announced today that its Partner Joseph Guardarrama has been selected to the Los Angeles Business Journal's 2022 list "Leaders of Influence: Minority Attorneys." The publication writes that these outstanding Southern California attorneys who also happen to be minorities were selected for inclusion based on a "demonstration of impact made on the profession and on the Los Angeles community."

Key Points: 
  • LOS ANGELES, Feb. 3, 2022 /PRNewswire/ --Boutique political and government law firm Kaufman Legal Group announced today that its Partner Joseph Guardarrama has been selected to the Los Angeles Business Journal's 2022 list "Leaders of Influence: Minority Attorneys.
  • "Joe is an exceptionally skilled attorney who constantly demonstrates his ability to deliver the highest level of services and strategic thinking to the firm's clients," said Kaufman Legal Group Founding Partner Stephen J. Kaufman .
  • Guardarrama has provided ongoing counsel and representation to some of California's most prominent elected officials in California and Washington, D.C., including U.S.
  • With offices in Los Angeles and Sacramento, Kaufman Legal Group offers a full spectrum of legal services connected to the political process at the federal, state and local levels.

Kainomyx Announces New Funding to Advance Programs Focused on Malaria and Other Parasitic Diseases

ACT, Leishmaniasis, Biology, Artemisinin, Degenerative disease, Biochemistry, Goal, Parasitism, Drug development, PALO, Bill & Melinda Gates Foundation, Time, Open philanthropy (doctrine), Malaria, Cell, Stanford University, Health, Cytoskeleton, Bill, Therapy, GLOBE, Combination, Doctor of Philosophy, Biophysics, Pharmaceutical industry

Together, they share a conviction that there is a critical need for new therapeutic innovations for treating malaria, leishmaniasis, and other parasitic diseases.

Key Points: 
  • Together, they share a conviction that there is a critical need for new therapeutic innovations for treating malaria, leishmaniasis, and other parasitic diseases.
  • Kainomyx is focusing on targeting the cytoskeletal proteins of parasites to develop small molecule therapeutics targeted at malaria and other parasitic diseases.
  • In just over one year, Kainomyx has been successful in raising ~$15.5M to advance its programs on neglected tropical diseases with a primary focus on malaria.
  • In addition, Kainomyx received a grant of $1.97M from the Bill & Melinda Gates Foundation to advance Kainomyxs program in malaria therapeutics.

Pure Earth Receives $8 Million to Expand Work to Solve the Global Lead Poisoning Crisis

Retrieved on: 
Tuesday, October 19, 2021
Philanthropy, Health, Consumer, Environment, Children, Foundation, General Health, Cosmetics, Global Alliance, Atmosphere, Policy, Conduct, Spice, Paint, Pregnancy, Biophysical environment, Organization, Awareness, Growth, Disability in Canada, UNICEF, Support, Water, Open philanthropy (doctrine), Lead, Lead poisoning, Global Health, Recycling, Program, Research, Poisoning, Low, GiveWell, Cancer, Solution, Soil, Global Alliance on Health and Pollution, Environment, Lithium, Medical imaging, Environmental remediation, Agriculture, Pure Earth, Protecting Every Child’s Potential, PURE EARTH, PROTECTING EVERY CHILD’S POTENTIAL

We are pleased to announce that GiveWell recommended an incubation grant of $8 million to Pure Earth to expand work on addressing lead poisoning.

Key Points: 
  • We are pleased to announce that GiveWell recommended an incubation grant of $8 million to Pure Earth to expand work on addressing lead poisoning.
  • The grant will also be part of the Protecting Every Childs Potential (PECP) initiative , founded in 2020 by Pure Earth, Clarios Foundation and UNICEF to prevent childrens exposure to lead.
  • The grant will expand Pure Earths work combatting lead poisoning over the next three years to:
    Identify likely sources of lead exposure in 25 low- and middle-income countries;
    Implement interventions to reduce lead exposure from key sources;
    Conduct baseline and endline analyses of blood lead levels to evaluate the effectiveness of the interventions.
  • Pure Earth has addressed toxic pollution in over 120 project locations through assessment, remediation, risk mitigation, awareness raising and more.